Back to top

oncology-screening: Archive

Urmimala Biswas

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

EXASPositive Net Change GHNegative Net Change TEMNegative Net Change

Bryan Hayes

Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026

Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

LLYPositive Net Change

Zacks Equity Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.

ADMAPositive Net Change EDITNegative Net Change COGTPositive Net Change ARQTNegative Net Change

Zacks Equity Research

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

MRKPositive Net Change GILDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change